INT2416

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.59
First Reported 1979
Last Reported 2010
Negated 1
Speculated 2
Reported most in Abstract
Documents 92
Total Number 95
Disease Relevance 42.24
Pain Relevance 36.50

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

mitochondrion (MAOA) small molecule metabolic process (MAOA) oxidoreductase activity (MAOA)
Anatomy Link Frequency
brain 8
MT2 3
platelet 3
blood 3
central nervous system 2
MAOA (Homo sapiens)
Pain Link Frequency Relevance Heat
monoamine 244 100.00 Very High Very High Very High
Dopamine 737 99.92 Very High Very High Very High
sSRI 327 99.92 Very High Very High Very High
tricyclic antidepressant 200 99.92 Very High Very High Very High
Central nervous system 73 99.92 Very High Very High Very High
Catecholamine 22 99.92 Very High Very High Very High
noradrenaline 18 99.68 Very High Very High Very High
antagonist 102 99.64 Very High Very High Very High
agonist 408 99.56 Very High Very High Very High
Nicotine 1122 99.52 Very High Very High Very High
Disease Link Frequency Relevance Heat
Nicotine Addiction 803 99.98 Very High Very High Very High
Adverse Drug Reaction 7 99.82 Very High Very High Very High
Depression 1657 99.68 Very High Very High Very High
Pressure And Volume Under Development 109 99.62 Very High Very High Very High
Depressive Disorder 30 99.54 Very High Very High Very High
Disease 1503 99.52 Very High Very High Very High
Migraine With Aura 1 99.24 Very High Very High Very High
Schizophrenia 83 98.92 Very High Very High Very High
Panic Disorder 546 98.80 Very High Very High Very High
Neuropathic Pain 5 98.72 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
While nearly complete MAO inhibition has been said to be required for direct behavioral changes to occur, partial MAO inhibition (reductions of 25-75 percent in enzyme activity) or selective inhibition of either the MAO-A or MAO-B form of the enzyme-especially after longer term inhibitor administration-lead to readily demonstrable alterations in the sensitivity of both animals and man to a variety of exogenous agents, and are also associated with a number of biological changes, including those involving neuroendocrine, blood pressure, and sleep mechanisms.
Negative_regulation (inhibition) of MAO in blood
1) Confidence 0.59 Published 1980 Journal Schizophr Bull Section Abstract Doc Link 6103577 Disease Relevance 0.06 Pain Relevance 0.23
While nearly complete MAO inhibition has been said to be required for direct behavioral changes to occur, partial MAO inhibition (reductions of 25-75 percent in enzyme activity) or selective inhibition of either the MAO-A or MAO-B form of the enzyme-especially after longer term inhibitor administration-lead to readily demonstrable alterations in the sensitivity of both animals and man to a variety of exogenous agents, and are also associated with a number of biological changes, including those involving neuroendocrine, blood pressure, and sleep mechanisms.
Negative_regulation (inhibition) of MAO in blood
2) Confidence 0.59 Published 1980 Journal Schizophr Bull Section Abstract Doc Link 6103577 Disease Relevance 0.06 Pain Relevance 0.23
Plasma from both subject groups (10-100 microliters) inhibited platelet and synaptosomal MAO in a dose-dependent manner to approximately the same degree at each time interval.
Negative_regulation (inhibited) of MAO in platelet
3) Confidence 0.59 Published 1992 Journal Neuropsychobiology Section Abstract Doc Link 1407477 Disease Relevance 0.33 Pain Relevance 0.49
The results indicate that although human plasma contains endogenous substances which inhibit MAO activity, alterations in their concentration are probably not responsible for the previously reported transient changes in platelet MAO activity in PMS.
Negative_regulation (inhibit) of MAO in plasma associated with dismenorea
4) Confidence 0.59 Published 1992 Journal Neuropsychobiology Section Abstract Doc Link 1407477 Disease Relevance 0.40 Pain Relevance 0.48
In human cortex, inhibition of MAO by preincubation with pargyline (10 micro M) abolished the TCP effect.
Negative_regulation (inhibition) of MAO in cortex
5) Confidence 0.58 Published 1997 Journal Life Sci. Section Abstract Doc Link 9048963 Disease Relevance 0 Pain Relevance 0.17
Upon preincubation with TCP, the stimulation of [3H]BFI binding was dose-dependently related to a simultaneous inhibition of MAO.
Negative_regulation (inhibition) of MAO
6) Confidence 0.58 Published 1997 Journal Life Sci. Section Abstract Doc Link 9048963 Disease Relevance 0 Pain Relevance 0.15
Incubation with clorgyline and deprenyl, probe inhibitors of MAO-A and MAO-B, respectively, showed that [14C]sumatriptan was metabolized by MAO-A; there was no evidence of P450 involvement in its metabolism.
Negative_regulation (inhibitors) of MAO associated with sumatriptan
7) Confidence 0.58 Published 1994 Journal Biochem. Pharmacol. Section Abstract Doc Link 8161354 Disease Relevance 0 Pain Relevance 0.59
Incubation with clorgyline and deprenyl, probe inhibitors of MAO-A and MAO-B, respectively, showed that [14C]sumatriptan was metabolized by MAO-A; there was no evidence of P450 involvement in its metabolism.
Negative_regulation (inhibitors) of MAO associated with sumatriptan
8) Confidence 0.58 Published 1994 Journal Biochem. Pharmacol. Section Abstract Doc Link 8161354 Disease Relevance 0 Pain Relevance 0.59
MAO activity assayed with 100 microM [14C]5HT or 10 microM [14C]PEA was sensitive to selective inhibitors of MAO A and MAO B, respectively.
Negative_regulation (inhibitors) of MAO
9) Confidence 0.58 Published 2009 Journal Med. Sci. Monit. Section Body Doc Link 19789505 Disease Relevance 0.08 Pain Relevance 0
MAO activity with 50 microM [14C]PEA was partially inhibited by clorgyline, and total inhibition was achieved only by the combination of clorgyline and semicarbazide, suggesting the presence of SSAO.
Negative_regulation (inhibited) of MAO
10) Confidence 0.58 Published 2009 Journal Med. Sci. Monit. Section Body Doc Link 19789505 Disease Relevance 0.08 Pain Relevance 0
MAO activity assayed with 100 microM [14C]5HT or 10 microM [14C]PEA was sensitive to selective inhibitors of MAO A and MAO B, respectively.
Negative_regulation (inhibitors) of MAO
11) Confidence 0.58 Published 2009 Journal Med. Sci. Monit. Section Body Doc Link 19789505 Disease Relevance 0.08 Pain Relevance 0
These drugs inhibited MAO activity as expected; however, an atypical biphasic response was observed with the tertiary amine tricyclic, clomipramine, and, to a somewhat lesser extent, with two other tertiary amine tricyclics, imipramine and amitriptyline, when benzylamine was used as the substrate in human tissue preparations.
Negative_regulation (inhibited) of MAO associated with endep
12) Confidence 0.57 Published 1988 Journal Naunyn Schmiedebergs Arch. Pharmacol. Section Abstract Doc Link 3244400 Disease Relevance 0 Pain Relevance 0.35
As a result, inhibition of monoamine oxidase (MAO) does not seem like an unreasonable approach to the treatment of PD depression.
Negative_regulation (inhibition) of monoamine oxidase associated with depression, disease and monoamine
13) Confidence 0.57 Published 2008 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2515908 Disease Relevance 1.31 Pain Relevance 0.66
Moclobemide is a novel benzamide reversible inhibitor of monoamine oxidase A and has clinical efficacy in a wide spectrum of depressive illness including endogenous and non-endogenous depression, in younger adults and in the elderly. 2.
Negative_regulation (inhibitor) of monoamine oxidase A associated with depression and monoamine
14) Confidence 0.57 Published 1993 Journal Prog. Neuropsychopharmacol. Biol. Psychiatry Section Abstract Doc Link 8255982 Disease Relevance 0.27 Pain Relevance 0.29
Clinical studies in humans have shown that amphetamine, which is a more potent inhibitor of MAO-A than phentermine, does not inhibit MAO-A at therapeutic doses.
Negative_regulation (inhibit) of MAO-A
15) Confidence 0.57 Published 1999 Journal Synapse Section Abstract Doc Link 10231134 Disease Relevance 0.17 Pain Relevance 0.13
With the advent of reversible, specific inhibitors of MAO-A (RIMAs) there is less potential for dietary and drug interaction.
Negative_regulation (inhibitors) of MAO-A
16) Confidence 0.57 Published 1992 Journal Psychopharmacology (Berl.) Section Abstract Doc Link 1546140 Disease Relevance 0 Pain Relevance 0.12
Clorgyline, a specific inhibitor of MAO-A, was less effective in inhibiting M12 formation.
Negative_regulation (inhibitor) of MAO
17) Confidence 0.49 Published 2007 Journal Drug Metab. Dispos. Section Abstract Doc Link 17881661 Disease Relevance 0 Pain Relevance 0.12
Selegiline is an irreversible inhibitor of MAO enzymes.
Negative_regulation (inhibitor) of MAO
18) Confidence 0.47 Published 2007 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2656289 Disease Relevance 0.29 Pain Relevance 0.32
Since the drug is an irreversible (suicide) enzyme inhibitor, the drug elimination half-life is less relevant and the duration of MAO enzyme inhibition is dependent on the rate of de novo enzyme synthesis.
Negative_regulation (inhibition) of MAO associated with suicidal behaviour
19) Confidence 0.47 Published 2007 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2656289 Disease Relevance 0.10 Pain Relevance 0.17
In addition, MAO inhibition is accompanied by marked changes in the sensitivity of the organism to some dietary constituents (e.g., tyramine, tryptophan, and other amines and amine precursors) as well as to many drugs (e.g., sympathomimetics, opiates, reserpine, and caffeine).
Negative_regulation (inhibition) of MAO associated with opiate
20) Confidence 0.43 Published 1980 Journal Schizophr Bull Section Abstract Doc Link 6103577 Disease Relevance 0 Pain Relevance 0.26

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox